Coeptis Therapeutics Holdings, INC

Z Squared Inc. has terminated its At Market Offering and Committed Equity Forward Purchase agreements, citing sufficient operating runway and a desire to eliminate potential dilution.

Z Squared Inc. has amended its Letter of Intent for the acquisition of Skycore Digital LLC, extending the drop-dead date and eliminating the break-up fee.

Z Squared Inc. has entered into a Sales Agreement to offer and sell up to $300 million of its common stock through Roth Capital Partners, LLC.

Z Squared Inc. announced the appointment of Jeffery Harris as Chief Technology Officer, effective June 24, 2026, coinciding with the company's binding letter of intent to acquire a majority stake in Paradox Data LLC.

Z Squared Inc. announced the completion of a $15.3 million equity financing and its inclusion in the Russell 3000 and Russell 2000 Indexes, bolstering its AI infrastructure strategy.

Z Squared Inc. announced a $50 million committed equity forward purchase agreement with LucentHash / Data Part Capital to fund its AI infrastructure buildout.

Coeptis Therapeutics reported a significant increase in cash and equity driven by capital raises, alongside a strategic shift towards biotechnology and AI-powered marketing, despite widening net losses.

Coeptis Therapeutics reports increased cash and new revenue from its technology segment, alongside a planned biotech spin-out and ongoing significant losses.

Coeptis Therapeutics Holdings, Inc. files its Form 10-Q for the quarter ended March 31, 2025, detailing its financial condition and operational progress in its biotechnology and technology divisions.

Coeptis Therapeutics Holdings reported its third quarter 2024 results, highlighting ongoing product development and strategic partnerships while navigating financial challenges.

Coeptis Therapeutics Holdings reported a net loss of $6.04 million for the six months ended June 30, 2024, while continuing to focus on product development and strategic partnerships.

Coeptis Therapeutics Holdings has filed an amended 10-Q report to reclassify notes receivable as subscription receivables after an accounting evaluation.

Coeptis Therapeutics Holdings, Inc. reports a net loss of $12.28 million for 2025, driven by increased operating expenses, while strategically expanding its technology segment and pursuing a merger and spin-out of its biotech operations.

Coeptis Therapeutics Holdings, Inc. has filed an amendment to its 2024 Annual Report on Form 10-K to include its previously omitted Executive Compensation Clawback Policy, ensuring compliance with SEC and Nasdaq rules.

Coeptis Therapeutics Holdings, Inc. files its 2024 10-K, highlighting its focus on cell therapy technologies, strategic partnerships, and financial results.

Coeptis Therapeutics Holdings, Inc. has filed an amendment to its 2023 annual report to correct the classification of subscription receivables on its balance sheet.

Coeptis Therapeutics Holdings, Inc. released its 2023 annual report, highlighting continued development of its product pipeline and strategic partnerships, while also noting significant operating losses.

Coeptis Therapeutics Holdings, Inc. has filed an amended 10-K to restate its 2022 financials due to an error in accounting for a convertible promissory note.

Christopher Ryan Schadel, Chief Marketing Officer of Z Squared Inc., was granted 2,806 Restricted Stock Units (RSUs) as a supplemental award.

BSG Series CM, LLC reports a pro rata distribution of all Z Squared Inc. common stock to its members, ceasing its reporting obligations.

Adam Craig Sohn, a Director at Z Squared Inc., was granted 9,868 Restricted Stock Units (RSUs) on April 27, 2026, with a grant-date fair value of $150,000.

Z Squared Inc. Chief Marketing Officer, Christopher Ryan Schadel, has been granted stock options and restricted stock units as part of his executive employment agreement.

Z Squared Inc. reports the grant of a stock option to Co-Chief Executive Officer David Halabu for 500,000 shares.

Z Squared Inc. reports that Director Bryan Eric Fuerst was granted 9,868 Restricted Stock Units (RSUs) on April 27, 2026, as part of his independent director compensation.

Coeptis Therapeutics Holdings is asking shareholders to approve a reverse stock split and the issuance of up to $20 million in securities at its upcoming annual meeting.

Z Squared Inc. has filed a registration statement for the potential resale of 100,000 shares of common stock issuable upon the exercise of outstanding warrants.

Z Squared Inc. has filed a registration statement for the resale of up to 41,584,562 shares of common stock by existing securityholders.

Coeptis Therapeutics is filing an amendment to its S-1 registration statement to allow selling stockholders to resell up to 3,919,349 shares of common stock.

Coeptis Therapeutics files an amended S-1 registration statement for the resale of up to 3,919,349 shares of common stock by selling stockholders, including shares issuable under a Standby Equity Purchase Agreement with YA II PN, LTD.

Coeptis Therapeutics files an S-1 registration statement for the resale of up to 3,919,349 shares of common stock by selling stockholders, including shares issuable under a Standby Equity Purchase Agreement with Yorkville.

BSG Series CM, LLC has completed a pro rata distribution of all its Z Squared Inc. common stock to its members, terminating its reporting obligation.

BSG Series CM, LLC reports an 80.73% beneficial ownership stake in Z Squared Inc. following the completion of a merger transaction.

Vanguard Capital Management has disclosed a beneficial ownership of 3.41% in Z Squared Inc., holding over 1.75 million shares.

Vanguard Capital Management and its affiliates have reported beneficial ownership of 5.57% of Coeptis Therapeutics Holdings Inc. common stock as of March 31, 2026.

Vanguard Capital Management has reported beneficial ownership of 5.57% of Coeptis Therapeutics Holdings Inc. common stock as of March 31, 2026.

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Coeptis Therapeutics Holdings Inc. due to an internal realignment.

The Vanguard Group and its affiliates reported a 6.35% beneficial ownership stake in Coeptis Therapeutics Holdings Inc. as of December 31, 2025.